

Kazuya Shimura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1350392/publications.pdf>

Version: 2024-02-01

24
papers

1,013
citations

567281

15
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

1332
citing authors

#	ARTICLE	IF	CITATIONS
1	Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). <i>Journal of Virology</i> , 2008, 82, 764-774.	3.4	330
2	Sporadic on/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E1269-E1278.	7.1	135
3	CXCR4 Stimulates Macropinocytosis: Implications for Cellular Uptake of Arginine-Rich Cell-Penetrating Peptides and HIV. <i>Chemistry and Biology</i> , 2012, 19, 1437-1446.	6.0	103
4	Elvitegravir: A New HIV Integrase Inhibitor. <i>Antiviral Chemistry and Chemotherapy</i> , 2009, 20, 79-85.	0.6	86
5	Design of Peptide-based Inhibitors for Human Immunodeficiency Virus Type 1 Strains Resistant to T-20*. <i>Journal of Biological Chemistry</i> , 2009, 284, 4914-4920.	3.4	41
6	Resistance Profiles of Novel Electrostatically Constrained HIV-1 Fusion Inhibitors. <i>Journal of Biological Chemistry</i> , 2010, 285, 39471-39480.	3.4	37
7	Potent CXCR4 Antagonists Containing Amidine Type Peptide Bond Isosteres. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 477-480.	2.8	33
8	Synonymous mutations in stem-loop III of Rev responsive elements enhance HIV-1 replication impaired by primary mutations for resistance to enfuvirtide. <i>Antiviral Research</i> , 2009, 82, 67-72.	4.1	25
9	Structure-activity relationship study of pyrimido[1,2-c][1,3]benzothiazin-6-imine derivatives for potent anti-HIV agents. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 6434-6441.	3.0	25
10	Concise synthesis and anti-HIV activity of pyrimido[1,2-c][1,3]benzothiazin-6-imines and related tricyclic heterocycles. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 6792.	2.8	24
11	Human retroviral antisense mRNAs are retained in the nuclei of infected cells for viral persistence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	23
12	Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. <i>Cell Reports</i> , 2021, 36, 109385.	6.4	23
13	Structure-activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4557-4561.	2.2	22
14	Identification of anti-HIV agents with a novel benzo[4,5]isothiazolo[2,3-a]pyrimidine scaffold. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 1447-1452.	3.0	19
15	Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat. <i>Antiviral Research</i> , 2010, 87, 179-186.	4.1	17
16	Design and synthesis of biotin- or alkyne-conjugated photoaffinity probes for studying the target molecules of PD 404182. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2079-2087.	3.0	14
17	Investigations of possible prodrug structures for 2-(2-mercaptophenyl)tetrahydropyrimidines: reductive conversion from anti-HIV agents with pyrimidobenzothiazine and isothiazolopyrimidine scaffolds. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 4706-4713.	2.8	14
18	Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors. <i>Retrovirology</i> , 2016, 13, 70.	2.0	10

#	ARTICLE	IF	CITATIONS
19	Impact of HIV-1 infection pathways on susceptibility to antiviral drugs and on virus spread. <i>Virology</i> , 2015, 484, 364-376.	2.4	9
20	Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 908-915.	2.8	6
21	HIV-1 Resistance Mechanism to an Electrostatically Constrained Peptide Fusion Inhibitor That Is Active against T-20-Resistant Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4035-4038.	3.2	6
22	Comprehensive <i>In Vitro</i> Analysis of Simian Retrovirus Type 4 Susceptibility to Antiretroviral Agents. <i>Journal of Virology</i> , 2013, 87, 4322-4329.	3.4	6
23	Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors. <i>Biochemistry and Biophysics Reports</i> , 2019, 20, 100687.	1.3	3
24	Elvitegravir: an emerging HIV integrase inhibitor. <i>Future HIV Therapy</i> , 2008, 2, 411-418.	0.4	2